Compare Definium Therapeutics Inc. Common Shares (DFTX) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs RLX Technology Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while RLX Technology Inc trades at $1.73 (market cap $2.11B). The key difference: Definium Therapeutics Inc. Common Shares is far larger — about 2.2× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.78% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and RLX Technology Inc for 34 Days on average.
| DFTX | RLX | |
|---|---|---|
Market Cap | $4.71B | $2.11B |
Volume | 1,966,636 | 621,808 |
Sector | Health | Consumer Staples |
52-Week High | $48.45 | $2.57 |
52-Week Low | $10.68 | $1.68 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $3.67B | $844.50M |
Dividend Yield | — | 5.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RLX Technology trades at $1.73, down 1.76% with a bearish technical signal. The stock recently hit 52-week lows amid margin compression despite 14.8% revenue growth in Q2 2026. Valuation appears reasonable with P/E of 15.55 and P/B below 1, but earnings misses in recent quarters raise execution concerns. International expansion now drives 70% of revenue following European acquisitions.
The outlook remains challenged by consecutive earnings misses and technical weakness, though discounted valuation and international growth provide potential upside. Key risks include sustained margin pressure and integration challenges from recent acquisitions. With only one analyst covering and maintaining a hold rating, institutional conviction appears limited.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
